Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Encorafenib

FDA-approved product (capsule, oral), marketed as Braftovi.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Encorafenib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Colorectal adenocarcinoma
  • Colorectal cancer
  • Colorectal neoplasm
  • Cutaneous melanoma
  • Melanoma
  • Metastatic melanoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
B-raf serine-threonine kinase (braf) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae35.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Encorafenib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Encorafenib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations

    NCT07178717 · start 2025-10

    Registered record
    Registry ID
    NCT07178717
    Conditions
    Colo-rectal Cancer
    Interventions
    Rechalange with bevacizumab + encorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-10
    Completion
    2028-08
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColo-rectal Cancer
    InterventionRechalange with bevacizumab + encorafenib
    PhasePhase 2
    Registry statusNot yet recruiting

  • UK ENcorafenib and BInimetinib Real-world Study in Melanoma

    NCT07022457 · start 2025-07-31

    Registered record
    Registry ID
    NCT07022457
    Conditions
    Metastatic Melanoma, BRAF V600 Mutation Positive
    Interventions
    Encorafenib + Binimetinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2025-07-31
    Completion
    2028-01-13
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Melanoma, BRAF V600 Mutation Positive
    InterventionEncorafenib + Binimetinib
    PhaseNot recorded
    Registry statusActive not recruiting

  • Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

    NCT06887088 · start 2025-05-29

    Registered record
    Registry ID
    NCT06887088
    Conditions
    Melanoma BRAF V600E/K Mutated; Melanoma and Brain Metastases
    Interventions
    Encorafenib + Binimetinib; cemiplimab+fianlimab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-05-29
    Completion
    2028-01
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma BRAF V600E/K Mutated; Melanoma and Brain Metastases
    InterventionEncorafenib + Binimetinib; cemiplimab+fianlimab
    PhasePhase 2
    Registry statusRecruiting

  • Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer

    NCT07617610 · start 2025-05-25

    Registered record
    Registry ID
    NCT07617610
    Conditions
    Metastatic Colorectal Cancer; BRAF V600E Mutation
    Interventions
    Longitudinal translational sampling
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-05-25
    Completion
    2030-09
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Colorectal Cancer; BRAF V600E Mutation
    InterventionLongitudinal translational sampling
    PhaseNot recorded
    Registry statusRecruiting

  • Real-life Pharmacological Monitoring of Encorafenib-Binimetinib in the Treatment of Metastatic Melanoma

    NCT06774989 · start 2025-01-02

    Registered record
    Registry ID
    NCT06774989
    Conditions
    Melanoma (Skin)
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-01-02
    Completion
    2028-01
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma (Skin)
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Personalized Medicine for Advanced Biliary Cancer Patients

    NCT05615818 · start 2024-07-18

    Registered record
    Registry ID
    NCT05615818
    Conditions
    Biliary Tract Neoplasms
    Interventions
    Futibatinib; Ivosidenib; Zanidatamab; Trastuzumab; Neratinib; Encorafenib; Binimetinib; Niraparib; Cisplatin; Gemcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-07-18
    Completion
    2028-06
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiliary Tract Neoplasms
    InterventionFutibatinib; Ivosidenib; Zanidatamab; Trastuzumab +6 more
    PhasePhase 3
    Registry statusRecruiting

  • Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.

    NCT06640166 · start 2024-06-03

    Registered record
    Registry ID
    NCT06640166
    Conditions
    Colorectal Carcinoma; Colorectal Neoplasms; Colorectal Tumor; Colorectal Adenocarcinoma; Colorectal Cancer (CRC); Colorectal Cancer; Colon Cancer; Colon Adenocarcinoma; Colon Carcinoma; Colon Neoplasm
    Interventions
    encorafenib + cetuximab + FOLFIRI
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-06-03
    Completion
    2026-06-30
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Carcinoma; Colorectal Neoplasms; Colorectal Tumor; Colorectal Adenocarcinoma +6 more
    Interventionencorafenib + cetuximab + FOLFIRI
    PhasePhase 2
    Registry statusRecruiting

  • Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy

    NCT06470880 · start 2024-06

    Registered record
    Registry ID
    NCT06470880
    Conditions
    Melanoma
    Interventions
    Adaptive Therapy; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2024-06
    Completion
    2027-06
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionAdaptive Therapy; Standard of Care
    PhasePhase 2
    Registry statusNot yet recruiting

  • Combination Therapy for BRAF-V600E Metastatic CRCm

    NCT06411600 · start 2024-05-17

    Registered record
    Registry ID
    NCT06411600
    Conditions
    Metastatic Colorectal Cancer
    Interventions
    Encorafenib; Cetuximab; Bevacizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-05-17
    Completion
    2029-05-01
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Colorectal Cancer
    InterventionEncorafenib; Cetuximab; Bevacizumab
    PhasePhase 2
    Registry statusRecruiting

  • Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

    NCT06194929 · start 2024-03-20

    Registered record
    Registry ID
    NCT06194929
    Conditions
    Cutaneous Melanoma; Brain Metastases
    Interventions
    Defactinib; Avutometinib; Encorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-03-20
    Completion
    2030-01-15
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCutaneous Melanoma; Brain Metastases
    InterventionDefactinib; Avutometinib; Encorafenib
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

    NCT05710406 · start 2023-08-16

    Registered record
    Registry ID
    NCT05710406
    Conditions
    Colon Adenocarcinoma; Microsatellite Stable Colon Carcinoma; Stage IIB Colon Cancer AJCC v8; Stage IIC Colon Cancer AJCC v8; Stage III Colon Cancer AJCC v8
    Interventions
    Encorafenib; Cetuximab; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Patient Observation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2023-08-16
    Completion
    2034-06-01
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColon Adenocarcinoma; Microsatellite Stable Colon Carcinoma; Stage IIB Colon Cancer AJCC v8; Stage IIC Colon Cancer AJCC v8 +1 more
    InterventionEncorafenib; Cetuximab; Biospecimen Collection; Computed Tomography +2 more
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

    NCT05639413 · start 2023-07-24

    Registered record
    Registry ID
    NCT05639413
    Conditions
    Metastatic Colorectal Cancer; BRAF V600E Mutation Positive
    Interventions
    Collection of blood samples
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-07-24
    Completion
    2028-07
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Colorectal Cancer; BRAF V600E Mutation Positive
    InterventionCollection of blood samples
    PhaseNot applicable
    Registry statusRecruiting

  • A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma

    NCT05926960 · start 2023-06-13

    Registered record
    Registry ID
    NCT05926960
    Conditions
    Melanoma
    Interventions
    encorafenib; binimetinib; pembrolizumab; ipilimumab; nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2023-06-13
    Completion
    2026-02-02
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    Interventionencorafenib; binimetinib; pembrolizumab; ipilimumab +1 more
    PhasePhase 2
    Registry statusTerminated

  • ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

    NCT05743036 · start 2023-02-27

    Registered record
    Registry ID
    NCT05743036
    Conditions
    Metastatic Colorectal Cancer
    Interventions
    ZN-c3; Encorafenib; Cetuximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2023-02-27
    Completion
    2025-07-09
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Colorectal Cancer
    InterventionZN-c3; Encorafenib; Cetuximab
    PhasePhase 1
    Registry statusTerminated

  • Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer

    NCT05706779 · start 2023-02-13

    Registered record
    Registry ID
    NCT05706779
    Conditions
    Colorectal Cancer; BRAF V600E Mutation Positive
    Interventions
    Encorafenib Oral Capsule + Cetuximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-02-13
    Completion
    2029-05-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer; BRAF V600E Mutation Positive
    InterventionEncorafenib Oral Capsule + Cetuximab
    PhasePhase 2
    Registry statusRecruiting